EuroMedtech™ is the annual medical technology conference that provides collaboration opportunities to medtech CEOs, large corporation business development executives, investors and service providers.

EuroMedtech™ 2012 brings together the myriad sectors of the medtech industry, creating a forum dedicated to forging partnerships between large companies and innovators, public and private companies and investors, institutes and industry. EuroMedtech caters to companies involved in all parts of the advanced medical technology industry, from those serving mainline therapeutic categories such as orthopedics and cardiovascular, through diagnostics, imaging and eHealth, to those involved in platform technologies such as biomaterials and regenerative medicine. Also attending are companies serving the industry, such as manufacturers, law firms, CROs and distributors.

The event features EBD Group’s sophisticated, web-based partnering system, partneringONE®, the life science’s leading conference networking solution that enables delegates to efficiently mine a large pool of potential partners and pre-arrange private one-to-one meetings.
EuroMedtech also features 15-minute presentations of medical technology innovations by start-ups and established firms, insightful panel discussions on industry developments and business development trends, and opportunities for informal networking.

We invite you to join us in Grenoble for Europe’s most intensely productive advanced medical technology event of the year.

For more information: www.ebdgroup.com/emt

More details

Find an actor

4à6 de BioAlps - Selexis SA20.09.2017

Les "4à6" de BioAlps sont une série d'événements organisés dans chacun des 7 cantons de Suisse occidentale.

Welcome To Health Valley

Building on skills honed over the centuries, western Switzerland has become a world leader in biotech.
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn